Autifony Therapeutics recently announced that it has initiated a UK-based phase one clinical trial for AUT00063, a pharmaceutical treatment for hearing loss and tinnitus.
The randomized, placebo controlled study will investigate the safety, tolerability, and pharmacokinetics of orally administered single and multiple dose regimens of AUT00063 in about 60 young and elderly volunteers. The study is expected to be completed in Q1 2014.
AUT00063 is being developed as a treatment for age-related hearing loss and tinnitus. Despite the fact that 50% of those aged over 60 suffer from age-related hearing loss and 10% of the population suffer from some form of tinnitus, there are currently no effective pharmacological treatments for either condition.
AUT00063 is a novel pharmaceutical that targets auditory processing in the brain. Deficits in these central mechanisms are believed to contribute to hearing difficulties in the elderly as well as the emergence of tinnitus.
SOURCE: Autifony Therapeutics
